Wosulin (New) 30/70 Injection 100 IU 3 ml Cartridge

Wosulin (New) 30/70 Injection 100 IU 3 ml Cartridge is an intermediate-acting and a short-acting type of insulin. It is a combination of two medicines such as Insulin Isophane (70%) & Human insulin (30%). It is prescribed to treat type 1 and type 2 diabetes mellitus in adults & children.

It works by controlling blood sugar levels in people with diabetes. It should be taken with food at the same time each day to get effective results. Don't take more than the recommended dose.​

• Type 1 and Type 2 diabetes mellitus

Like any other medicine, Wosulin (New) 30/70 Injection 100 IU 3 ml Cartridge   also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Hypoglycemia (low blood glucose level)
• Injection site reactions (pain, swelling, redness)
• Weight gain

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Dosage of this injection determined by the doctor as per the type of disease and overall health condition of the patient. Correct way of injecting Wosulin (New) 30/70 Injection 100 IU 3 ml Cartridge under the skin teach by your healthcare provider.
• A meal containing carbohydrates should be taken within 30 minutes after taking this injection. Do not stop taking it unless your doctor tells you to.​
  

• Wosulin (New) 30/70 Injection 100 IU 3 ml Cartridge is an intermediate-acting and a short-acting type of insulin. It is a combination of two medicines such as Insulin Isophane (70%) & Human insulin (30%).
• In which human insulin has a fast onset of action and Insulin isophane has a prolonged duration of action. Together both of these ensure rapid as well as consistent sugar control by facilitating the reuptake of sugar in muscle & fat cells also suppressing sugar production in the liver.​​
  

• Erickson, T. N., Devine, E. B., O’Young, T. S., Hanson, L. J., French, B., & Brennan, C. (2006). Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine. American journal of health-system pharmacy, 63(19), 1862-1871. https://pubmed.ncbi.nlm.nih.gov/16990633/
• Engström, L. H. (1990). Insulin pen for administration of isophane insulin. Practical Diabetes International, 7(4), 162-164. https://pubmed.ncbi.nlm.nih.gov/20513316/
• Chandler, C., Gryniewicz, C. M., Pringle, T., & Cunningham, F. (2008). Insulin temperature and stability under simulated transit conditions. American Journal of Health-System Pharmacy, 65(10), 953-963.https://pubmed.ncbi.nlm.nih.gov/18463345/
• Lauritzen, T., Pramming, S., Gale, E. A., Deckert, T., & Binder, C. (1982). Absorption of isophane (NPH) insulin and its clinical implications. Br Med J (Clin Res Ed), 285(6336), 159-162.
• Home, P. (1986). Human insulin. British Medical Journal (Clinical research ed.), 292(6520), 625.
• Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., ... & Siebenhofer, A. (2007). Long‐acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane database of systematic reviews, (2). https://pubmed.ncbi.nlm.nih.gov/17443605/